The Pandemic Agreement's Hardest Question Was Never Whether Countries Could Agree. It's Whether They Can Share.
Negotiations over pathogen access and benefit sharing expose the central tension in pandemic diplomacy: countries need rapid access to biological information while also expecting equitable access to the vaccines, diagnostics, and therapeutics their data helps create.
The WHO Pandemic Agreement's core achievement was getting countries to agree, in principle, that pandemic response requires shared obligations. Its hardest remaining work is the Pathogen Access and Benefit Sharing system, which has to answer a much less comfortable question: when a country shares a novel pathogen's genetic sequence, what exactly does it get back, and how fast?
Speed and equity pull against each other
Rapid pathogen sharing saves lives; every week of delay in identifying a new variant or emerging threat is a week vaccine and diagnostic developers don't have. But the countries most likely to first detect emerging pathogens are frequently not the countries with manufacturing capacity to benefit quickly from what gets built using their data. Negotiators are trying to design a system that doesn't ask lower-resource countries to keep providing early-warning data on trust, while also not slowing detection down with bureaucratic benefit-sharing requirements attached to every sample.
The unresolved piece is implementation, not principle
Even a well-negotiated PABS framework only works if individual countries have the laboratory systems, legal frameworks, and manufacturing or licensing relationships to actually receive the benefits the agreement promises. That's an implementation gap that will persist well after the diplomatic text is finalized, and it's the part most countries are least prepared to act on: turning a benefit-sharing entitlement into actual doses, diagnostics, or technology transfer arriving inside their own health system.